Nephropathy in siblings of African Americans with overt type 2 diabetic nephropathy

被引:28
|
作者
Satko, SG
Langefeld, CD
Daeihagh, P
Bowden, DW
Rich, SS
Freedman, BI
机构
[1] Wake Forest Univ, Sch Med, Dept Internal Med, Nephrol Sect, Winston Salem, NC 27157 USA
[2] Wake Forest Univ, Sch Med, Dept Nephrol, Winston Salem, NC 27157 USA
[3] Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA
[4] Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA
关键词
familial aggregation; type 2 diabetic nephropathy (DN); chronic kidney disease (CKD); African Americans (AAs); proteinuria; prevention;
D O I
10.1053/ajkd.2002.34888
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: The prevalence of abnormal proteinuria and elevated serum creatinine (sCr) concentrations in diabetic sibs of African Americans (AAs) with overt type 2 diabetic nephropathy (DN) or end-stage renal disease (ESRD) is unknown. Methods: We measured urine albumin-creatinine (UAC) ratio, sCr, and hemoglobin A(1c) (HbA(1c)) in 211 sibs from 66 families (66 unrelated index cases with overt type 2 DN/ESRD, 132 of their diabetic sibs, and 13 of their nondiabetic sibs). Overt DN was defined as a UAC ratio of 1,000 mg/g or greater or ESRD attributed to diabetes. All index cases had at least one diabetic sib screened. Results: Given similar mean ages and body mass indices, nondiabetic sibs had lower UAC ratios and HbA(1c) values compared with diabetic sibs and index cases (Wilcoxon's rank-sum test, all P < 0.006). More than 60% of index cases had at least one diabetic sib with a UAC ratio of 30 or greater and 300 mg/g or less. Nearly 35% of index cases had at least one sib with a UAC ratio greater than 300 mg/g. Nearly 24% of index cases had at least one sib with an elevated sCr level (greater than or equal to1.4 mg/dL [124 mumol/L] in women, greater than or equal to1.6 mg/dL [141 mumol/L] in men). Conclusion: Asymptomatic elevations in urinary albumin excretion and sCr levels are frequently present in diabetic sibs of AA individuals with overt type 2 DN. Diabetic sibs of AA individuals with type 2 DN should be the focus of intensive screening and intervention programs to slow the current epidemic of diabetic ESRD. (C) 2002 by the National Kidney Foundation, Inc.
引用
收藏
页码:489 / 494
页数:6
相关论文
共 50 条
  • [1] INCIPIENT AND OVERT DIABETIC NEPHROPATHY IN AFRICAN-AMERICANS WITH NIDDM
    DASMAHAPATRA, A
    BALE, A
    RAGHUWANSHI, MP
    REDDI, A
    BYRNE, W
    SUAREZ, S
    NASH, F
    VARAGIANNIS, E
    SKURNICK, JH
    DIABETES CARE, 1994, 17 (04) : 297 - 304
  • [2] Diabetic nephropathy in African Americans
    Crook, ED
    AMERICAN JOURNAL OF HYPERTENSION, 2001, 14 (06) : 132S - 138S
  • [3] A genome scan for diabetic nephropathy in African Americans
    Bowden, DW
    Colicigno, CJ
    Langefeld, CD
    Sale, MM
    Williams, A
    Anderson, PJ
    Rich, SS
    Freedman, BI
    KIDNEY INTERNATIONAL, 2004, 66 (04) : 1517 - 1526
  • [4] Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy
    Berl, T
    Hunsicker, LG
    Lewis, JB
    Pfeffer, MA
    Porush, JG
    Rouleau, JL
    Drury, PL
    Esmatjes, E
    Hricik, D
    Parikh, CR
    Raz, I
    Vanhille, P
    Wiegmann, TB
    Wolfe, BM
    Locatelli, F
    Goldhaber, SZ
    Lewis, EJ
    ANNALS OF INTERNAL MEDICINE, 2003, 138 (07) : 542 - 549
  • [5] Avosentan for Overt Diabetic Nephropathy
    Mann, Johannes F. E.
    Green, Damian
    Jamerson, Kenneth
    Ruilope, Luis M.
    Kuranoff, Susan J.
    Littke, Thomas
    Viberti, Giancarlo
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 21 (03): : 527 - 535
  • [6] Sulodexide Fails to Demonstrate Renoprotection in Overt Type 2 Diabetic Nephropathy
    Packham, David K.
    Wolfe, Rory
    Reutens, Anne T.
    Berl, Tomas
    Heerspink, Hiddo Lambers
    Rohde, Richard
    Ivory, Sara
    Lewis, Julia
    Raz, Itamar
    Wiegmann, Thomas B.
    Chan, Juliana C. N.
    de Zeeuw, Dick
    Lewis, Edmund J.
    Atkins, Robert C.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 23 (01): : 123 - 130
  • [7] Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy
    Rossing, P
    Rossing, K
    Gæde, P
    Pedersen, O
    Parving, HH
    DIABETES CARE, 2006, 29 (05) : 1024 - 1030
  • [8] Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy
    Rossing, P
    Rossing, K
    Gaede, PH
    Pedersen, OB
    Parving, HH
    DIABETOLOGIA, 2005, 48 : A75 - A75
  • [9] Cardiovascular outcomes in the irbesartan diabetic nephropathy trial (IDNT) of patients with type 2 diabetes and overt nephropathy.
    Berl, T
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 651A - 651A
  • [10] Comparative characteristics of overt diabetic nephropathy in type 1 and type 2 diabetes.
    Bain, RP
    Ratner, RE
    Weurth, JP
    DIABETOLOGIA, 1998, 41 : A287 - A287